Rostral anterior cingulate cortex activity and early symptom improvement during treatment for major depressive disorder - PubMed (original) (raw)

Randomized Controlled Trial

Rostral anterior cingulate cortex activity and early symptom improvement during treatment for major depressive disorder

Alexander S Korb et al. Psychiatry Res. 2011.

Abstract

In treatment trials for major depressive disorder (MDD), early symptom improvement is predictive of eventual clinical response. Clinical response may also be predicted by elevated pretreatment theta (4-7Hz) current density in the rostral anterior cingulate (rACC) and medial orbitofrontal cortex (mOFC). We investigated the relationship between pretreatment EEG and early improvement in predicting clinical outcome in 72 MDD subjects across three placebo-controlled treatment trials. Subjects were randomized to receive fluoxetine, venlafaxine, or placebo. Theta current density in the rACC and mOFC was computed with Low-Resolution Brain Electromagnetic Tomography (LORETA). An analysis of covariance examining week-8 Hamilton Depression Rating Scale (HamD) percent change, showed a significant effect of week-2HamD percent change, and a significant three-way interaction of week-2HamD percent change×treatment×rACC. Medication subjects with robust early improvement showed almost no relationship between rACC theta current density and final clinical outcome. However, in subjects with little early improvement, rACC activity showed a strong relationship with clinical outcome. The model examining the mOFC showed a trend in the three-way interaction. A combination of pretreatment rACC activity and early symptom improvement may be useful for predicting treatment response.

Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

PubMed Disclaimer

Figures

Figure 1

Figure 1. Regions of Interest

A sagittal view of the ROIs used in our analyses: rACC in red, mOFC in blue.

Figure 2

Figure 2. Pretreatment rACC Theta Current Density and Week Eight HamD Percent Change by Early Improvement

Lines indicate the average marginal effects of rACC theta current density (centered) on Week 8 HamD percent change at different levels of early improvement. That is, the lines reflect the expected relationship between rACC theta current density and outcome at a given degree of early improvement. Medication subjects with robust early improvement (e.g. 50%) show a weak relationship between rACC theta current density and clinical outcome, while medication subjects with little to no early improvement (e.g. 0%) show a strong relationship between rACC theta current density and clinical outcome.

Figure 3

Figure 3. Week 2 response and Wk8HamPctChg by rACC Theta (centered)

Scatter plots show individual subjects' log rACC theta current density (centered) and week 8 HamD percent change. Red dots depict subjects that met response criteria at week 2 (HamD percent change >= 50%), and are therefore termed Early Responders. Blue dots depict subjects that did not meet response criteria at week 2, and are therefore termed Early NonResponders. Red and blue lines represent the fitted regression lines for the Early Responders and Early NonResponders respectively.

References

    1. Aklillu E, Karlsson S, Zachrisson OO, Ozdemir V, Agren H. Association of MAOA gene functional promoter polymorphism with CSF dopamine turnover and atypical depression. Pharmacogenetics and Genomics. 2009;19:267–275. -PubMed
    1. Bares M, Brunovsky M, Kopecek M, Stopkova P, Novak T, Kozeny J, Hoschl C. Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot study. Journal of Psychiatric Research. 2007;41:319–325. -PubMed
    1. Brody AL, Saxena S, Silverman DH, Alborzian S, Fairbanks LA, Phelps ME, Huang SC, Wu HM, Maidment K, Baxter LR., Jr Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Research. 1999;91:127–139. -PubMed
    1. Cook IA, Hunter AM, Abrams M, Siegman B, Leuchter AF. Midline and right frontal brain function as a physiologic biomarker of remission in major depression. Psychiatry Research: Neuroimaging. 2009;174:152–157. -PMC -PubMed
    1. Cook IA, Leuchter AF, Morgan M, Witte E, Stubbeman WF, Abrams M, Rosenberg S, Uijtdehaage SH. Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology. 2002;27:120–131. -PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources